

SUPPLEMENTAL PRELIMINARY AMENDMENT
U.S. Appl. No. 10/781,841

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-28. (Cancelled).

Claim 29. (New) An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide consisting of the amino acid sequence of SEQ ID NO:34, and
- (b) a polypeptide consisting of the amino acid sequence of SEQ ID NO:34 in which one or several amino acids are deleted, substituted or added, wherein said polypeptides have cranial nerve growth activity and/or nerve regenerating activity.

Claim 30. (New) An isolated DNA sequence selected from the group consisting of:

- (a) a DNA sequence consisting of the nucleotide sequence of SEQ ID NO:35 or a sequence complementary thereto, and
- (b) a DNA sequence which hybridizes with the DNA sequence defined in (a) above under washing conditions of 0.1 x SSC/0.05% SDS at 50°C, wherein the DNA sequence is capable of expressing a polypeptide having cranial nerve growth activity and/or nerve regenerating activity.

Claim 31. (New) An expression vector comprising the DNA sequence of Claim 30.

Claim 32. (New) An isolated transformant comprising the expression vector of Claim 31.

SUPPLEMENTAL PRELIMINARY AMENDMENT
U.S. Appln. No. 10/781,841

Claim 33. (New) A process of producing a polypeptide having cranial nerve growth activity and/or nerve regenerating activity, comprising culturing the transformant of Claim 32 under suitable conditions so as to express said polynucleotide, and recovering said polypeptide having cranial nerve growth activity and/or nerve regenerating activity.

Claim 34. (New) A recombinant protein obtained by the process of Claim 33.

Claim 35. (New) An antibody which binds to the polypeptide of Claim 29 or the recombinant protein of Claim 34.